Tjellesen L, Christiansen C, Rødbro P
Acta Med Scand. 1984;215(5):411-5. doi: 10.1111/j.0954-6820.1984.tb17672.x.
Bone metabolism was estimated by serum alkaline phosphatase (index of bone formation) and fasting urinary excretions of calcium and hydroxyproline (indices of bone resorption) in a group of early postmenopausal women and a group of 70-year-old women, during 12 months' treatment with 1,25-dihydroxycholecalciferol (1,25(OH)2D3), and compared to oestrogen/gestagen treatment or placebo treatment. The groups treated with 1,25(OH)2D3 did not show any change in bone metabolism, neither in bone resorption nor in bone formation, during the treatment period when compared to the placebo group, whereas treatment with female hormones decreased both bone resorption and bone formation.
在一组绝经后早期女性和一组70岁女性中,通过血清碱性磷酸酶(骨形成指标)以及钙和羟脯氨酸的空腹尿排泄量(骨吸收指标)来评估骨代谢。这些女性接受了12个月的1,25 - 二羟胆钙化醇(1,25(OH)2D3)治疗,并与雌激素/孕激素治疗或安慰剂治疗进行比较。与安慰剂组相比,接受1,25(OH)2D3治疗的组在治疗期间骨代谢没有任何变化,无论是骨吸收还是骨形成方面;而使用女性激素治疗则降低了骨吸收和骨形成。